SCHEMBL29891783

SCHEMBL29891783

Cc1ccccc1-c1noc(C2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.50
ALDH1A1 P00352 2/20 0.49
HTT P42858 2/20 0.49
THRB P10828 2/20 0.49
TSHR P16473 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
GAA P10253 1/20 0.48
SMO Q99835 3/20 0.48
GPR119 Q8TDV5 2/20 0.48
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8146112 1.00 HCRTR1 (0.50) HCRTR1ALDH1A1HTTTHRBTSHR
SCHEMBL4138796 0.89 HSD11B1 (0.57) HCRTR1ALDH1A1HTTTHRBTSHR
SCHEMBL4138801 0.89 HSD11B1 (0.57) HCRTR1ALDH1A1HTTTHRBTSHR
SCHEMBL12580552 0.89 ALDH1A1 (0.63) HCRTR1ALDH1A1HTTTHRBTSHR
SCHEMBL12580532 0.86 ALDH1A1 (0.55) HCRTR1ALDH1A1HTTTSHRSMN1; SMN2
SCHEMBL1653518 0.86 TUBB4A (0.60) THRBTSHRSMN1; SMN2LMNAGAA
SCHEMBL25168815 0.85 TUBB4A (0.55) HCRTR1ALDH1A1HTTTHRBTSHR
SCHEMBL2901393 0.84 TUBB4A (0.58) THRBTSHRSMN1; SMN2LMNAGAA
SCHEMBL4423384 0.83 GPR119 (0.59) ALDH1A1HTTTSHRSMN1; SMN2LMNA
SCHEMBL15808398 0.83 PARP1 (0.45) ALDH1A1HTTTHRBTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 CN disclosed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 CN disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 EP disclosed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA HCRTR1 4576/4885ALDH1A1 3915/4885HTT 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.